Member Info for Num4

Remember Sierra had a big raise recently, it could always be possible that they could take an option in the drug for a collaboration into trials. Tim won't be giving this one away for free, but the way Sierra have handled CHK1 has been great, maybe we will see a nice sum from them for a small stake in the drug - after all they know we can deliver the goods.

and why haven't we seen this compelling activity in the form of an RNS? You would think they would want to show the pharma community just how well their drug works in the models they have now tested in and got the results for.
You don't spend years designing and testing to not release the results at the clinical selection stage.

Tim's phone engaged all morning

Parker should now be able to announce the II's that are going to support the progress to trials and then before we enter PI or shortly thereafter it will be bought. If the space is as hot as it seems then it shouldn't be long to wait until someone takes options or licenses it straight away. Fact is - this is going to trials, one way or another.

http://www.proactiveinvestors.co.uk/companies/news/204493/sareum-to-further-develop-potential-best-in-class-autoimmune-disease-treatment-204493.html

Of course they have to use the word "potentially". They haven't done all of the tests or the trials. Only when all competitors are licensed they can truely say who is the best in the class. For time to say its the best-in-class now,,lol. We would never get a deal if he came out with that.
From the data we have available Tim is saying it is better than competitors, so potentially we are best-in-class, but until you get through the trials you don't know.

IMO after that release and the availability of the data to those under NDA, for one of them big pharma names not to double down on this target would be crazy. What good is 3 maybe 4 years of selling a drug, if they get licensed, when Sareum's is best-in-class.

Sareum reaches preclinical milestone in TYK2/JAK1 inhibitor programme - Potent, selective small molecule inhibitor of TYK2/JAK1 selected for further development as a potential treatment for autoimmune diseases

Sareum Holdings plc (AIM: SAR), the specialist small molecule drug development company, announces it has made the formal selection of a development candidate from its TYK2 inhibitor programme to advance through preclinical development as a potential new treatment for autoimmune diseases.

The candidate molecule, SDC-1801, demonstrated high selectivity for TYK2 and JAK1 kinases (particularly over related JAK2 and JAK3), compelling activity in disease models of psoriasis and rheumatoid arthritis, the potential for once-daily oral dosing and a good early safety profile. Closely related molecules, including SAR-20347, have also shown good activity in models of inflammatory bowel disease and systemic lupus erythematosus (lupus). These attributes strongly support the progression of SDC-1801 into preclinical development and, pending satisfactory progress, advancement into human clinical trials, which could begin in 2020.

The preclinical development candidate SDC-1801 was nominated from a novel series of compounds designed and identified by Sareum following a rigorous selection process. The company is also completing its assessment of further dual TYK2/JAK1 inhibitors for the potential treatment of certain cancers and/or as a back-up to SDC-1801 and expects to nominate this candidate in the near future.

TYK2 and JAK1 are members of the Janus Kinase (JAK) family of protein kinase enzymes with roles in pro-inflammatory responses in autoimmune diseases and tumour cell proliferation in certain cancers. Members of the JAK family are the targets of several marketed and clinical-stage drugs for cancer and autoimmune diseases, although there are currently no marketed products specifically targeting TYK2.Â

Dr Tim Mitchell, CEO of Sareum, commented: "TYK2 and JAK1 have emerged in recent years as important targets for new drugs with potential to treat a broad range of autoimmune diseases. This has naturally led to some serious interest from the major pharmaceutical companies, including  Pfizer, Bristol-Myers Squibb and Celgene having their own clinical and preclinical programmes in this area. With SDC-1801, we believe we are entering this space with a strong candidate that exhibits potentially best-in-class features. We intend to focus our resources on advancing SDC-1801 through preclinical development and into clinical trials over the next 18 months. At the same time, we will continue our discussions with potential licence partners for this exciting drug candidate."

Sareum has an ongoing co-development agreement with SRI International (Menlo Park, CA, USA) to develop TYK2 inhibitors in autoimmune diseases. Sareum retains commercialisation rights for these and other TYK2 inhibitors with profiles optimised for oncology indications.

So there it is boys. The new name of the best-in-class drug for autoimmune disease.
Continuing discussions, wonder how many people want this, well done Tim and John.

Taken from year end report June 2017:
"The Group will continue to develop its oncology programmes
and, in particular, the Aurora+FLT3 project will be advanced
through preclinical development into Phase 1 clinical trials.
The TYK2 inhibitor, targeting autoimmune diseases, will also
be progressed in conjunction with SRI International and the use
of the Company’s TYK2 inhibitors as cancer therapeutics will be
developed. Commercially, significant licensing deals will be sought
to realise the high value inherent in the Company’s technology."

http://www.sareum.com/files/3515/1111/5757/Sareum_Annual_Report_2017.pdf
page 14

I wouldn't be surprised if BMS doubled down on tyk2 by taking options on ours too.

Correct me if I am wrong Thoth, but as we can see from the tweet link the big pharma are branching their targets for tyk2 with a single compound.
Sareum have 2 different compounds for better treatment of the specific types of targets.
We certainly won't be first in class but I have full confidence in us being best-in-class, Tim's strategy all along.

This exposure by QD is great stuff and it all adds further confidence in Sareum to strike a big options deal with one of their compounds. The advanced work we are doing pre-clinical can only be a good thing for a deal with increased payments.
We really do have a great chance here for some sort of license/options deal worth a pretty penny.

Lets hope the tyk2 news flow comes shortly.

is Parker to deliver the institutions which are going to support Sareum's tyk2 compounds through to PI - simple. Very achievable and all resources and contacts should be available to Parker. They can then utilise a CRO to sort the trials out. Parker must have a job description of bringing them investment and to date he has only managed to convince his wife. Poor Show Parker.

Would it be beneficial to Sierra to omit all reference to a 2 man band in a small office in England when you are trying to attract investors, would they rather tell everyone they got the compound from ICR and CRUK only.
Makes you wonder what Sareum actually did on Chk1, if you speak to Tim, it's his oldest child yet Sierra want nothing to do with the Dad and just like the foster parents, ICR/CRUK.
You go back in SAR reports and find reference to chk1 from an early stage. Sierra or dare I say ProNAI have a history of misleading investors, least they learnt their lesson and got it in the contract that they don't have to mention Sareum.

From March 2018:
"Thank you for supporting Sierra.



Our licensing agreement for SRA737 is with the CRT Pioneer Fund LP, of which CRT – the commercialization arm of CRUK - is a shareholder; we are contractually obligated to reference the role of ICR in developing the compound under the terms of our license. No such contractual obligation extends to Sareum, whose involvement substantially predates our engagement with CRT Pioneer Fund, CRT and ICR, and who have subsequently not been engaged in the development program for the asset.



Notwithstanding, we certainly have acknowledged Sareum’s role in the early advancement of SRA737. In our press release announcing the licensing of SRA737 from the CRT Pioneer Fund LP, we note that SRA737 “was discovered and initially developed by scientists in the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research (ICR) in collaboration with Sareum Holdings plc (LSE AIM: SAR), with funding provided by Cancer Research UK, the ICR and Sareum. The program was licensed in September 2013 to the CRT Pioneer Fund, a specialist cancer investment fund established by Sixth Element Capital LLP (6EC), Cancer Research Technology (CRT) and the European Investment Fund (EIF) and managed by 6EC.”

http://investor.sierraoncology.com/2016-09-27-ProNAi-Licenses-Oncology-Drug-Targeting-DNA-Damage-Response-Checkpoint-Kinase-1-Chk1-from-CRT-Pioneer-Fund-UK
"

Was it from James Smith ?

Hi Ray, I asked the same question a few months back and got the exact, word for word reply.

When BMS release their data it confirms that the tyk2/JAK1 approach is valid, then when you compare the BMS molecule selectivity against JAK2 with ours you will see ours is superior, meaning less side effects. But wait, you can't compare ours as they have removed the factsheets with that information on. BMS figures are publically available.
Maybe we will hear something after the 13th, but for sure Sareum will be on the tweet machine.

...When Aston Martin float..Perhaps the only way some of us will own such luxury, unless Sareum drop the rns.

Sareum have had ~£11million to get to where they are, this was documented in a presentation which will be available on private investor website if you look through them from the last few years. That's why they consider themselves as extremely efficient with cash. I don't disagree either, it is nothing in the pharma world and we have a drugs in PII with Sierra.
I don't think the cashburn rate is as high as you expect - what are we infact spending money on this year, Chk1 is zero, Aurora will be a contractors fee for looking at the formulation issue, tyk2 would have been the big expense in paying for further animal model studies, that would have come to an end now and the data we have will be worth the wait - already mentioned about it being excessive data to reduce any time spent in pre-clinical. We have a cream that is being tested on human skin cells already. A lot of positives yet to come from Sareum especially on tyk2, 2 compounds and a cream.
With Tim tweeting about BMS data which is due mid-September they will want to announce their data around the same time. BMS will go from having there compound on the podium to it being divested and them buying Sareums version. If Sareums is proven to be better why waste your money.
GLA

https://www.google.com/amp/www.proactiveinvestors.co.uk/companies/amp/news/124923 2 years old but informal discussions are not out of the question. Sareum's current portfolio is a nice addition to any company, along with the SKIL platform they are an attractive purchase. Hopefully it doesn't get to October for the update. We wait and watch.

Lets hope they have their end game in sight Thoth.